Trial
NCT02774291
Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes
Early Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Albert Einstein College of Medicine
Collaborators
National Cancer Institute (NCI)
Condition
HLA-A2 Positive Cells Present
Intervention
Aldesleukin
Why stopped
Due to lack of accrual the study was formally terminated on 01-JUL-2020. Primary Completion and Study Completion Dates have been revised based accordingly based on respective definitions
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-08-04